



September 30, 2022

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE Prime Market)
Contact person: Kenji Yamada, Senior Vice President,
Corporate Administration Headquarters
(TEL. +81-3-6711-5200)

**Japan Lifeline and Boston Scientific Japan Reach a Basic Agreement
on RF Needle Radiofrequency Transseptal Needle**

Japan Lifeline Co., Ltd. (“the Company”) announced today that at the Board of Directors meeting held the same day, it has determined to reach a basic agreement with Boston Scientific Japan K.K. (“Boston Scientific Japan”) regarding the RF Needle (“the Product”), a radiofrequency transseptal needle manufactured by Baylis Medical Company, Inc. (“Baylis Medical”) after the end of February 2023, when the Japanese exclusive distribution agreement with Baylis Medical expires.

The agreement with Boston Scientific Japan is as follows:

- Japan Lifeline will continue to sell the Product until the end of March 2023
- Boston Scientific Japan will exclusively sell the Product from April 2023
- After April 1 2023, Japan Lifeline will cooperate in the sales at specific facilities agreed upon between the two companies until the end of December 2025.

Since its launch in April 2013, Japan Lifeline has successfully promoted the RF Needle as its one-and-only product, and the Product has been widely used for ablation treatment of atrial fibrillation and other procedures today. As Boston Scientific Corporation (USA) acquired Baylis Medical in February 2022, Japan Lifeline has held discussions with Boston Scientific Japan on the Japanese distribution of the Product, and has reached this basic agreement.

The Company expects that this agreement has no material impact on the consolidated financial results for the fiscal year ending March 31, 2023.